Sotagliflozin in Combination With Optimized Insulin Therapy in Adults With Type 1 Diabetes: The North American inTandem1 Study
Open accessThe DOI matches its Crossref record; 40 of the 41 references it cites were found in a registry or an index.
Abstract
OBJECTIVE: Evaluate the efficacy and safety of the dual sodium–glucose cotransporter 1 (SGLT1) and SGLT2 inhibitor sotagliflozin in combination with optimized insulin in type 1 diabetes (T1D). RESEARCH DESIGN AND METHODS: The inTandem1 trial, a double-blind, 52-week phase 3 trial, randomized North American adults with T1D to placebo (n = 268), sotagliflozin 200 mg (n = 263), or sotagliflozin 400 mg (n = 262) after 6 weeks of insulin optimization. The primary end point was HbA1c change from baseline at 24 weeks. HbA1c, weight, and safety were also assessed through 52 weeks. RESULTS: From a mean baseline of 7.57%, placebo-adjusted HbA1c reductions were 0.36% and 0.41% with sotagliflozin 200 and 400 mg, respectively, at 24 weeks and 0.25% and 0.31% at 52 weeks (all P < 0.001). Among patients with a baseline HbA1c ≥7.0%, an HbA1c <7% was achieved by 15.7%, 27.2%, and 40.3% of patients receiving placebo, sotagliflozin 200 mg, and sotagliflozin 400 mg, respectively (P ≤ 0.003 vs. placebo) at 24 weeks. At 52 weeks, mean treatment differences between sotagliflozin 400 mg and placebo were −1.08 mmol/L for fasting plasma glucose, −4.32 kg for weight, and −15.63% for bolus insulin dose and −11.87% for basal insulin dose (all P < 0.001). Diabetes Treatment Satisfaction Questionnaire scores increased significantly by 2.5 points with sotagliflozin versus placebo (P < 0.001) at 24 weeks. Genital mycotic infections and diarrhea occurred more frequently with sotagliflozin. Adjudicated diabetic ketoacidosis (DKA) occurred in 9 (3.4%) and 11 (4.2%) patients receiving sotagliflozin 200 and 400 mg, respectively, and in 1 (0.4%) receiving placebo. Severe hypoglycemia occurred in 17 (6.5%) patients from each sotagliflozin group and 26 (9.7%) patients receiving placebo. CONCLUSIONS: In a 1-year T1D study, sotagliflozin combined with optimized insulin therapy was associated with sustained HbA1c reduction, weight loss, lower insulin dose, fewer episodes of severe hypoglycemia, improved patient-reported outcomes, and more DKA relative to placebo (ClinicalTrials.gov, NCT02384941).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“there is preliminary evidence that in select individuals with type 1 diabetes and excess adiposity, newer pharmacotherapy (i.e., glucagonlike peptide 1 receptor agonists or sodium -glucose cotransporter 2 inhibitors) (195,196) can decrease body weight and improve glycemia, though they are currently not indicated.”
From Nutrition Therapy for Adults With Diabetes or Prediabetes: A Consensus Report (2019) · cites this paper as [195]
Citations
Cites
Assessing Psychosocial Distress in Diabetes
Polonsky, W. H., Fisher, L., Earles, J., Dudl, R. J., Lees, J., Mullan, J., & Jackson, R. A. (2005) · Diabetes Care · doi:10.2337/diacare.28.3.626 · Cited by 1,575 · cited 4×
“At week 24, sotagliflozin-treated patient scores on the DDS2 decreased by 0.7 (20.9 to20.”
BackgroundInfluentialMiller, K. M., Foster, N. C., Beck, R. W., Bergenstal, R. M., DuBose, S. N., DiMeglio, L. A., Maahs, D. M., & Tamborlane, W. V. (2015) · Diabetes Care · doi:10.2337/dc15-0078 · Cited by 1,254
Peters, A. L., Buschur, E. O., Buse, J. B., Cohan, P., Diner, J. C., & Hirsch, I. B. (2015) · Diabetes Care · doi:10.2337/dc15-0843 · Cited by 849 · cited 1×
“has emerged as the major clinical concern around SGLT inhibition in T1D (17,18).”
BackgroundSelf-citationDapagliflozin improves muscle insulin sensitivity but enhances endogenous glucose production
Merovci, A., Solis-Herrera, C., Daniele, G., Eldor, R., Fiorentino, T. V., Tripathy, D., Xiong, J., Perez, Z., Norton, L., Abdul-Ghani, M. A., et al. (2014) · Journal of Clinical Investigation · doi:10.1172/jci70704 · Cited by 795
Bonner, C., Kerr-Conte, J., Gmyr, V., Queniat, G., Moerman, E., Thévenet, J., Beaucamps, C., Delalleau, N., Popescu, I., Malaisse, W. J., et al. (2015) · Nature Medicine · doi:10.1038/nm.3828 · Cited by 670
Outpatient Glycemic Control with a Bionic Pancreas in Type 1 Diabetes
Russell, S. J., El-Khatib, F. H., Sinha, M., Magyar, K. L., McKeon, K., Goergen, L. G., Balliro, C., Hillard, M. A., Nathan, D. M., & Damiano, E. R. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1314474 · Cited by 602 · cited 1×
“have been largely limited to insulin formulation and delivery innovations (1,5,6).”
BackgroundGarg, S. K., Weinzimer, S. A., Tamborlane, W. V., Buckingham, B. A., Bode, B. W., Bailey, T. S., Brazg, R. L., Ilany, J., Slover, R. H., Anderson, S. M., et al. (2017) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2016.0421 · Cited by 585 · cited 1×
“have been largely limited to insulin formulation and delivery innovations (1,5,6).”
BackgroundSelf-citationWeissberg-Benchell, J., Antisdel-Lomaglio, J., & Seshadri, R. (2003) · Diabetes Care · doi:10.2337/diacare.26.4.1079 · Cited by 551
Effects of sotagliflozin added to insulin in patients with type 1 diabetes
Garg, S. K., Henry, R. R., Banks, P., Buse, J. B., Davies, M. J., Fulcher, G. R., Pozzilli, P., Gesty-Palmer, D., Lapuerta, P., Simó, R., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1708337 · Cited by 417 · cited 2×
“incidence of DKA in patients with T1D (14).”
BackgroundSelf-citationAgiostratidou, G., Anhalt, H., Ball, D., Blonde, L., Gourgari, E., Harriman, K. N., Kowalski, A. J., Madden, P., McAuliffe-Fogarty, A. H., McElwee-Malloy, M., et al. (2017) · Diabetes Care · doi:10.2337/dc17-1624 · Cited by 397
Self-citation
Research works printed but not linked: 1
- Bradley, 1994, The Diabetes Treatment Satisfaction Questionnaire: DTSQ, 111
Cited by
Sotagliflozin in patients with diabetes and recent worsening heart failure
Bhatt, D. L., Szarek, M., Steg, P. G., Cannon, C. P., Leiter, L. A., McGuire, D. K., Lewis, J. B., Riddle, M. C., Voors, A. A., Metra, M., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2030183 · Cited by 1,868
Self-citationNutrition Therapy for Adults With Diabetes or Prediabetes: A Consensus Report
Evert, A. B., Dennison, M., Gardner, C. D., Garvey, W. T., Lau, K. H. K., MacLeod, J., Mitri, J., Pereira, R. F., Rawlings, K., Robinson, S., et al. (2019) · Diabetes Care · doi:10.2337/dci19-0014 · Cited by 1,496
Sotagliflozin in patients with diabetes and chronic kidney disease
Bhatt, D. L., Szarek, M., Pitt, B., Cannon, C. P., Leiter, L. A., McGuire, D. K., Lewis, J. B., Riddle, M. C., Inzucchi, S. E., Kosiborod, M. N., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2030186 · Cited by 1,205
Self-citationEmpagliflozin as Adjunctive to Insulin Therapy in Type 1 Diabetes: The EASE Trials
Rosenstock, J., Marquard, J., Laffel, L. M., Neubacher, D., Kaspers, S., Cherney, D. Z., Zinman, B., Skyler, J. S., George, J., Soleymanlou, N., et al. (2018) · Diabetes Care · doi:10.2337/dc18-1749 · Cited by 363
“higher doses is also reported similarly for sotagliflozin and dapagliflozin T1D programs (10,12).”
BackgroundSelf-citationCarbohydrate-based drugs launched during 2000−2021
Cao, X., Du, X., Jiao, H., An, Q., Chen, R., Fang, P., Wang, J., & Yu, B. (2022) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2022.05.020 · Cited by 267
Sarafidis, P., Ferro, C. J., Morales, E., Ortiz, A., Malyszko, J., Hojs, R., Khazim, K., Ekart, R., Valdivielso, J., Fouque, D., et al. (2019) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfy407 · Cited by 204
Danne, T., Cariou, B., Banks, P., Brandle, M., Brath, H., Franek, E., Kushner, J. A., Lapuerta, P., McGuire, D. K., Peters, A. L., et al. (2018) · Diabetes Care · doi:10.2337/dc18-0342 · Cited by 186
“Canada with a design identical to that of the current study, showed similar results (22).”
ResultSelf-citationCurrent and future therapies for type 1 diabetes
von Scholten, B. J., Kreiner, F. F., Gough, S. C. L., & von Herrath, M. (2021) · Diabetologia · doi:10.1007/s00125-021-05398-3 · Cited by 173
Novel Noninvasive Approaches to the Treatment of Obesity: From Pharmacotherapy to Gene Therapy
Angelidi, A. M., Belanger, M. J., Kokkinos, A., Koliaki, C. C., & Mantzoros, C. S. (2022) · Endocrine Reviews · doi:10.1210/endrev/bnab034 · Cited by 128
Combination therapy for kidney disease in people with diabetes mellitus
van Raalte, D. H., Bjornstad, P., Cherney, D. Z. I., de Boer, I. H., Fioretto, P., Gordin, D., Persson, F., Rosas, S. E., Rossing, P., Schaub, J. A., et al. (2024) · Nature Reviews Nephrology · doi:10.1038/s41581-024-00827-z · Cited by 127
SGLT2 inhibitors as adjunctive therapy for type 1 diabetes: Balancing benefits and risks
Taylor, S. I., Blau, J. E., Rother, K. I., & Beitelshees, A. L. (2019) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(19)30154-8 · Cited by 124
Goldenberg, R. M., Gilbert, J. D., Hramiak, I. M., Woo, V. C., & Zinman, B. (2019) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.13811 · Cited by 114
“This, coupled with patientreported enhanced treatment satisfaction and diminished diabetes distress, suggests that there are significant merits in considering SGLT inhibitors as adjuncts to insulin therapy in type 1 diabetes.(32,33)”
BackgroundThe emergence of obesity in type 1 diabetes
Kueh, M. T. W., Chew, N. W. S., Al-Ozairi, E., & le Roux, C. W. (2024) · International Journal of Obesity · doi:10.1038/s41366-023-01429-8 · Cited by 111
“Ef fi cacy: Sotagli fl ozin, a dual SGLT1 and SGLT2 inhibitor, was investigated in the Tandem phase 3 clinical trials [78, 79].”
BackgroundGarg, S. K., Peters, A. L., Buse, J. B., & Danne, T. (2018) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2018.0246 · Cited by 108
“14–18,20 Based on Due to their insulin-independent mechanism of action, SGLT2 or dual SGLT1 and 2 inhibitors lower total daily insulin dose requirements, which may be expected to increase ketosis.”
Self-citationSGLT2i and GLP-1 RA therapy in type 1 diabetes and reno-vascular outcomes: a real-world study
Anson, M., Zhao, S. S., Austin, P., Ibarburu, G. H., Malik, R. A., & Alam, U. (2023) · Diabetologia · doi:10.1007/s00125-023-05975-8 · Cited by 103
Musso, G., Gambino, R., Cassader, M., & Paschetta, E. (2019) · BMJ · doi:10.1136/bmj.l1328 · Cited by 94
Defining and characterising diabetic ketoacidosis in adults
Dhatariya, K. K. (2019) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2019.107797 · Cited by 93
“This makes direct comparison of DKA incidence rates between agents impossible [47,57,60,61].”
Backgroundvan Raalte, D. H., Bjornstad, P., Persson, F., Powell, D. R., de Cassia Castro, R., Wang, P. S., Liu, M., Heerspink, H. J. L., & Cherney, D. (2019) · Diabetes Care · doi:10.2337/dc19-0937 · Cited by 92
“cordance with international standards of good clinical practice and with approval by local institutional review boards (21,22).”
BackgroundMethodEdwards, K., Li, X., & Lingvay, I. (2023) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgac618 · Cited by 92
Insulin Resistance in Type 1 Diabetes: Pathophysiological, Clinical, and Therapeutic Relevance
Apostolopoulou, M., Lambadiari, V., Roden, M., & Dimitriadis, G. D. (2025) · Endocrine Reviews · doi:10.1210/endrev/bnae032 · Cited by 90
Management of Diabetic Ketoacidosis in Children and Adolescents with Type 1 Diabetes Mellitus
Castellanos, L. E., Tuffaha, M., Koren, D., & Levitsky, L. L. (2020) · Pediatric Drugs · doi:10.1007/s40272-020-00397-0 · Cited by 138
Obesity in Patients with Type 1 Diabetes: Links, Risks and Management Challenges
Vilarrasa, N., San Jose, P., Rubio, M. Á., & Lecube, A. (2021) · Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy · doi:10.2147/dmso.s223618 · Cited by 88
New advances in type 1 diabetes
Subramanian, S., Khan, F., & Hirsch, I. B. (2024) · BMJ · doi:10.1136/bmj-2023-075681 · Cited by 88
What does sodium‐glucose co‐transporter 1 inhibition add: Prospects for dual inhibition
Rieg, J. A. D., & Rieg, T. (2019) · Diabetes Obesity and Metabolism · doi:10.1111/dom.13630 · Cited by 93
He, Y., Haynes, W., Meyers, C. D., Amer, A., Zhang, Y., Mahling, P., Mendonza, A. E., Ma, S., Chutkow, W., & Bachman, E. (2019) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.13654 · Cited by 81
Moon, J. S., Kang, S., Choi, J. H., Lee, K. A., Moon, J. H., Chon, S., Kim, D. J., Kim, H. J., Seo, J. A., Kim, M. K., et al. (2024) · Diabetes & Metabolism Journal · doi:10.4093/dmj.2024.0249 · Cited by 90
Mathieu, C., Rudofsky, G., Phillip, M., Araki, E., Lind, M., Arya, N., Thorén, F., Scheerer, M. F., Iqbal, N., & Dandona, P. (2020) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.14060 · Cited by 71
“Changes in HbA1c, TDD and body weight observed in the present studywere consistent with those reported for the two higher doses of empagliflozin (10 and 25mg) in the EASEPhase III programme(28) and for sotagliflozin in the inTandem1 and 2 studies.(29,30)”
ResultSodium–Glucose Cotransporter 2 Inhibitors: A Case Study in Translational Research
Beitelshees, A. L., Leslie, B. R., & Taylor, S. I. (2019) · Diabetes · doi:10.2337/dbi18-0006 · Cited by 78
Dutta, S., Kumar, T., Singh, S., Ambwani, S. R., Charan, J., & Varthya, S. B. (2022) · Journal of Family Medicine and Primary Care · doi:10.4103/jfmpc.jfmpc_644_21 · Cited by 76
Danne, T., Cariou, B., Buse, J. B., Garg, S. K., Rosenstock, J., Banks, P., Kushner, J. A., McGuire, D. K., Peters, A. L., Sawhney, S., et al. (2019) · Diabetes Care · doi:10.2337/dc18-2149 · Cited by 64
“In the full inTandem1 and inTandem2 study populations, the incidence of documented hypoglycemia (by SMBG) and severe hypoglycemia was numerically lower with sotagliflozin 400 mg than with 200 mg (12,13).”
BackgroundMethodResultSelf-citationEfficacy and safety of sotagliflozin in patients with type 2 diabetes and severe renal impairment
Cherney, D. Z. I., Ferrannini, E., Umpierrez, G. E., Peters, A. L., Rosenstock, J., Carroll, A. K., Lapuerta, P., Banks, P. L., & Agarwal, R. (2021) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14513 · Cited by 73
Self-citationGlycaemic variability: The under‐recognized therapeutic target in type 1 diabetes care
Wilmot, E. G., Choudhary, P., Leelarathna, L., & Baxter, M. (2019) · Diabetes Obesity and Metabolism · doi:10.1111/dom.13842 · Cited by 72
Sotagliflozin: First Global Approval
Markham, A., & Keam, S. J. (2019) · Drugs · doi:10.1007/s40265-019-01146-5 · Cited by 64
Musso, G., Sircana, A., Saba, F., Cassader, M., & Gambino, R. (2020) · PLOS Medicine · doi:10.1371/journal.pmed.1003461 · Cited by 61
“Eight RCTs adopted insulin dose optimization prior to randomization [56,57,60,65,66,72,73].”
MethodPowell, D. R., Zambrowicz, B., Morrow, L., Beysen, C., Hompesch, M., Turner, S., Hellerstein, M., Banks, P., Strumph, P., & Lapuerta, P. (2020) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgz258 · Cited by 58
“For that SMBG analysis, SMBG targets, including PPG, were assessed by an independent insulin dose monitoring committee that provided feedback to investigators on insulin dose adjustment if standard-of-care glucose targets were not met (9).”
BackgroundMethodInfluentialSelf-citationLi, D., Liu, Y., Hidru, T. H., Yang, X., Wang, Y., Chen, C., Li, K. H. C., Tang, Y., Wei, Y., Tse, G., et al. (2021) · Frontiers in Endocrinology · doi:10.3389/fendo.2021.619586 · Cited by 63
“org 3 Study Characteristics and Quality Assessment A total of 37,068 patients received SGLT2i [dapagliflozin (27– 35), canagliflozin (36–43), empagliflozin (44–53), sotagliflozin (54, 55) and ertugliflozin (56–58)] and 29,617 patients received placebo.”
BackgroundZhang, H., Ding, L., Mi, L., Zhang, A.-K., Zhang, K., Jiang, Z., Yu, F., Yan, X.-X., Shen, Y.-J., & Tang, M. (2023) · European Journal of Preventive Cardiology · doi:10.1093/eurjpc/zwad356 · Cited by 58
Synthetic strategy and SAR studies of C-glucoside heteroaryls as SGLT2 inhibitor: A review
Haider, K., Pathak, A., Rohilla, A., Haider, M. R., Ahmad, K., & Yar, M. S. (2019) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2019.111773 · Cited by 55
Dejgaard, T. F., von Scholten, B. J., Christiansen, E., Kreiner, F. F., Bardtrum, L., von Herrath, M., Mathieu, C., Madsbad, S., & ADJUNCT ONE and ADJUNCT TWO Investigators (2021) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.14532 · Cited by 48
Mathieu, C., Dandona, P., Phillip, M., Oron, T., Lind, M., Hansen, L., Thorén, F., Xu, J., Langkilde, A. M., & on behalf of the DEPICT-1 and DEPICT-2 Investigators (2019) · Diabetes Care · doi:10.2337/dc18-1983 · Cited by 48
“90)mmol/L (155 [34]mg/dL) with dapagliflozin 5mg, 8.”
Hampp, C., Swain, R. S., Horgan, C., Dee, E., Qiang, Y., Dutcher, S. K., Petrone, A., Chen Tilney, R., Maro, J. C., & Panozzo, C. A. (2020) · Diabetes Care · doi:10.2337/dc19-1481 · Cited by 47
“The sotagliflozin clinical trials, referred to as trials 309 (9), 310 (10), and 312 (11), included patients with type 1 diabetes from North America, Europe and Israel, andworldwide, respectively, who were followed for 52 weeks (trials 309 and 310) or 24 weeks (trial 312) to”
BackgroundSGLT2i effect on atrial fibrillation: A network meta‐analysis of randomized controlled trials
Mariani, M. V., Manzi, G., Pierucci, N., Laviola, D., Piro, A., D’Amato, A., Filomena, D., Matteucci, A., Severino, P., Miraldi, F., et al. (2024) · Journal of Cardiovascular Electrophysiology · doi:10.1111/jce.16344 · Cited by 52
Optimising the Benefits of SGLT2 Inhibitors for Type 1 Diabetes
Evans, M., Hicks, D., Patel, D., Patel, V., McEwan, P. C., & Dashora, U. K. (2019) · Diabetes Therapy · doi:10.1007/s13300-019-00728-6 · Cited by 48
SGLT inhibitors for type 1 diabetes: proceed with extreme caution
Wolfsdorf, J. I., & Ratner, R. E. (2019) · Diabetes Care · doi:10.2337/dci19-0008 · Cited by 45
“Importantly, some patients using these medications off-label (14) and study participants (12,13) have presented with euglycemic DKA (near-normal or only”
BackgroundReducing Type 1 Diabetes Mortality: Role for Adjunctive Therapies?
Snaith, J. R., Holmes-Walker, D. J., & Greenfield, J. R. (2020) · Trends in Endocrinology & Metabolism · doi:10.1016/j.tem.2019.11.007 · Cited by 45
Maffei, P., Bettini, S., Busetto, L., & Dassie, F. (2023) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s240903 · Cited by 49
Glucagon-like peptide-1 receptor agonists as add-on therapy to insulin for type 1 diabetes mellitus
Tan, X., Pan, X., Wu, X., Zheng, S., Chen, Y., Liu, D., & Zhang, X. (2023) · Frontiers in Pharmacology · doi:10.3389/fphar.2023.975880 · Cited by 44
The double burden: type 1 diabetes and heart failure—a comprehensive review
Julián, M. T., de, A. P.-M., Julve, J., & Alonso, N. (2024) · Cardiovascular Diabetology · doi:10.1186/s12933-024-02136-y · Cited by 55
BOEDER, S. C., & Edelman, S. V. (2019) · Diabetes Obesity and Metabolism · doi:10.1111/dom.13749 · Cited by 44
“their insulin therapy optimized according to fasting and postprandial glucose targets for 6 weeks before randomization to sotagliflozin 200 or 400 mg, with insulin dosing adjustments continuing throughout the trial.(37) The inTandem2 trial (n = 782) was a study of similar design to inTandem1, but undertaken at multipl…”
BackgroundMethodBays, H. E., Kozlovski, P., Shao, Q., Proot, P., & Keefe, D. (2020) · Obesity · doi:10.1002/oby.22764 · Cited by 41
“A lower incidence of diarrhea is reported with sotagliflozin (27,28), suggesting that SGLT1 activity may not be completely inhibited by sotagliflozin in the clinical setting.”
BackgroundLu, J., Tang, L., Meng, H., Zhao, J., & Liang, Y. (2019) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.3169 · Cited by 41
“One report included 14 RCTs with 4591 participants(22): four included RCTs were of short duration (less than 12 weeks) with a relatively small sample size(5,7,32,33) and four were conference abstracts with incomplete outcomes.(11,14,17,18) Another report included 13 RCTs with 5397 participants, but only five of the in…”
BackgroundPeters, A. L., McGuire, D. K., Danne, T., Kushner, J. A., Rodbard, H. W., Dhatariya, K., Sawhney, S., Banks, P. L., Jiang, W., Davies, M. J., et al. (2020) · Diabetes Care · doi:10.2337/dc20-0924 · Cited by 44
“2017) (12), and inTandem2 conducted at 96 sites across Europe and Israel (May 2015 to June 2017) (13).”
BackgroundSelf-citationMedical and surgical management of obesity and diabetes: what's new?
Ammori, B. J., Skarulis, M. C., Soran, H., Syed, A. A., Eledrisi, M. S., & Malik, R. A. (2020) · Diabetic Medicine · doi:10.1111/dme.14215 · Cited by 40
Kang, S., Kang, S. M., Choi, J. H., Ko, S., Koo, B. K., Kwon, H.-S., Kim, M. K., Kim, S. Y., Kim, S., Kim, Y., et al. (2025) · Diabetes & Metabolism Journal · doi:10.4093/dmj.2025.0469 · Cited by 84
Li, K., & Xu, G. (2018) · Journal of Diabetes · doi:10.1111/1753-0407.12890 · Cited by 33
Posch, M. G., Walther, N., Ferrannini, E., Powell, D. R., Banks, P. L., Wason, S., & Dahmen, R. (2022) · Diabetes Care · doi:10.2337/dc21-2166 · Cited by 34
Self-citationBaker, C., Wason, S., Banks, P. L., Sawhney, S., Chang, A., Danne, T., Gesty‐Palmer, D., Kushner, J. A., McGuire, D. K., Mikell, F. L., et al. (2019) · Diabetes Obesity and Metabolism · doi:10.1111/dom.13825 · Cited by 30
Self-citationDanne, T., Pettus, J., Giaccari, A., Cariou, B., Rodbard, H. W., WEINZIMER, S. A., Bonnemaire, M., Sawhney, S., Stewart, J., Wang, S. Q., et al. (2019) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2019.0157 · Cited by 35
Self-citationRao, L., Ren, C., Luo, S., Huang, C., & Li, X. (2021) · Acta Diabetologica · doi:10.1007/s00592-021-01686-x · Cited by 29
Tang, X., Yan, X., Zhou, H., Huang, G., Niu, X., Jiang, H., Su, H., Yang, X., Li, X., & Zhou, Z. (2022) · Chinese Medical Journal · doi:10.1097/cm9.0000000000002075 · Cited by 31
Tseng, P., Zeng, B., Hsu, C.-W., Hung, C., Carvalho, A. F., Stubbs, B., Chen, Y., Chen, T., Lei, W., Chen, J.-J., et al. (2025) · BMC Medicine · doi:10.1186/s12916-025-04018-w · Cited by 36
Sotagliflozin: A Review in Type 1 Diabetes
Deeks, E. D. (2019) · Drugs · doi:10.1007/s40265-019-01230-w · Cited by 26
Tandon, S., Ayis, S. A., Hopkins, D. L., Harding, S., & Stadler, M. (2020) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14221 · Cited by 32
“Inclusion criteria for BMI were not mentioned in any of the studies assessing sotagliflozin.(51,53,55) For the study assessing ipragliflozin, the inclusion criteria for BMI ranged from 20.”
BackgroundKim, Y. J., Hwang, S. D., & Lim, S. K. (2020) · Frontiers in Endocrinology · doi:10.3389/fendo.2020.00553 · Cited by 24
Horii, T., Oikawa, Y., Atsuda, K., & Shimada, A. (2021) · Journal of Diabetes Investigation · doi:10.1111/jdi.13506 · Cited by 23
See, R. M., Teo, Y. N., Teo, Y. H., Syn, N. L. X., Yip, A. S. Y., Leong, S., Wee, C. F., Cheong, A. J. Y., Lee, C., Chan, M. Y., et al. (2021) · Pharmacology · doi:10.1159/000520903 · Cited by 27
STOUGAARD, E. B., Rossing, P. R., Vistisen, D., Banks, P. L., Girard, M., Davies, M. J., & Persson, F. (2023) · Diabetes Obesity and Metabolism · doi:10.1111/dom.15047 · Cited by 23
“Following randomization, participants entered a 24-week, double-blind, core treatment period (primary endpoint).(10,11) In the inTandem3 trial, after a 2-week, single-blind run-in period, during which all participants received placebo, eligible patients (similar criteria as in inTandem1 and 2) were randomly assigned,…”
BackgroundMethodSelf-citationShelke, V., Kale, A., Dagar, N., Habshi, T., & Gaikwad, A. B. (2023) · Food & Function · doi:10.1039/d3fo01379k · Cited by 23
Exploring Patient Preferences for Adjunct-to-Insulin Therapy in Type 1 Diabetes
Perkins, B. A., Rosenstock, J., Skyler, J. S., Laffel, L. M., Cherney, D. Z. I., Mathieu, C., Pang, C., Wood, R., Kinduryte, O., George, J. T., et al. (2019) · Diabetes Care · doi:10.2337/dc19-0548 · Cited by 25
Self-citationHalperin, I. J., Wicklow, B., Amed, S., Chambers, A., Courage, C., Cummings, E., Kirkland, P., MacKay, D., Nakhla, M., Punthakee, Z., et al. (2025) · Canadian Journal of Diabetes · doi:10.1016/j.jcjd.2025.01.001 · Cited by 22
Management of diabetic ketoacidosis in special populations
Eledrisi, M. S., Beshyah, S., & Malik, R. A. (2021) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2021.108744 · Cited by 27
SGLT inhibitors in type 1 diabetes: weighing efficacy and side effects
Janssens, B., Caerels, S., & Mathieu, C. (2020) · Therapeutic Advances in Endocrinology and Metabolism · doi:10.1177/2042018820938545 · Cited by 24
Antidiabetic lead compounds and targets for drug development
Tupas, G. D., Otero, M. C. B., Ebhohimen, I. E., Egbuna, C., & Aslam, M. (2020) · Elsevier eBooks · doi:10.1016/b978-0-12-817890-4.00008-1 · Cited by 29
van Raalte, D. H., & Bjornstad, P. (2020) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfz228 · Cited by 24
“41% in the inTandem 1 and inTandem 2 studies [82, 83].”
BackgroundSGLT2 inhibitors as metabolic modulators: beyond glycemic control in type 2 diabetes
Wu, Q., Zhang, J., Zhang, F., & Li, D. (2025) · Frontiers in Endocrinology · doi:10.3389/fendo.2025.1601633 · Cited by 38
“…or urinary tract infections, and had a lower incidence of severe hypoglycemia during a 24-week treatment period, although the risk of DKA still warrants caution (118, 119); and the 52-week treatment outcomes of sotagli fl ozin (400 mg) indicated risks of DKA and hypoglycemia (120, 121).”
Pettus, J., Kushner, J. A., Valentine, V., Wood, R., Pang, C., Paranjape, S., Berria, R., Deluzio, A., & Edelman, S. V. (2019) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2019.0027 · Cited by 22
Self-citationPharmacologic treatment options for type 1 diabetes: what’s new?
Nally, L. M., Sherr, J. L., Name, M. A. V., Patel, A., & Tamborlane, W. V. (2019) · Expert Review of Clinical Pharmacology · doi:10.1080/17512433.2019.1597705 · Cited by 26
“2% of patients receiving 200mg and 400 mg of sotagliflozin, respectively [58].”
BackgroundBode, B. W., Cengiz, E., Wadwa, R. P., Banks, P., Danne, T., Kushner, J. A., McGuire, D. K., Peters, A. L., Strumph, P., & Sawhney, S. (2021) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2020.0079 · Cited by 20
Self-citationLee, M. H., Paldus, B., Krishnamurthy, B., McAuley, S. A., Shah, R., Jenkins, A. J., & O’Neal, D. N. (2019) · Journal of Diabetes Science and Technology · doi:10.1177/1932296818822986 · Cited by 22
Al‐Ozairi, E., Irshad, M., Taghadom, E., SOJAN, L. G., Kandari, J. A., Alroudhan, D., & le Roux, C. W. (2023) · Obesity · doi:10.1002/oby.23677 · Cited by 21
“A similar result was also reported with the SGLT2i sotagliflozin when initiated by people with type 1 diabetes [19, 20].”
ResultA review of sotagliflozin for use in type 1 diabetes
Nuffer, W. A., Williams, B., & Trujillo, J. M. (2019) · Therapeutic Advances in Endocrinology and Metabolism · doi:10.1177/2042018819890527 · Cited by 20
Basic and Clinical Pharmaco-Therapeutics of SGLT2 Inhibitors: A Contemporary Update
Kalra, S., Shetty, K., Nagarajan, V. B., & Ved, J. (2020) · Diabetes Therapy · doi:10.1007/s13300-020-00789-y · Cited by 22
Rodbard, H. W., Giaccari, A., Lajara, R., Stewart, J. A., Strumph, P., Oliveira, J. H., Lapuerta, P., & Castro, R. D. C. (2020) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14127 · Cited by 21
“Slight differences in the patient populations between inTandem1 (conducted in North America) and inTandem2 (conducted in Europe and Israel) may somewhat limit interpretation of our results, as baseline BMI and CSII use were higher in the inTandem1 population.(8,9) However, the study designs were identical, and importa…”
BackgroundMethodResultInfluentialSelf-citationZou, H., Liu, L., Guo, J., Wang, H., Liu, S., Xing, Y., Deng, C., Xiao, Y., & Zhou, Z. (2020) · Journal of Diabetes Investigation · doi:10.1111/jdi.13387 · Cited by 21
Danne, T., Edelman, S. V., Frías, J. P., Ampudia‐Blasco, F. J., Banks, P., Jiang, W., Davies, M. J., & Sawhney, S. (2020) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14271 · Cited by 20
“Double-blind treatment with insulin optimization continued throughout the full 52-week trial, as previously described.(4,5)”
MethodSelf-citationSGLT Inhibitors for Type 1 Diabetes: An Obvious Choice or Too Good to Be True?
Riddle, M. C., & Cefalu, W. T. (2018) · Diabetes Care · doi:10.2337/dci18-0041 · Cited by 18
“Supplementing earlier small studies of combining an SGLTi with basal-bolus insulin for T1D, six reports of larger studies have now been published (12–17), two of them in this issue (16,18) and three in the September issue of Diabetes Care (14,15,17).”
BackgroundInfluentialChen, M.-B., Xu, R.-J., Zheng, Q.-H., Zheng, X.-W., & Wang, H. (2020) · Medicine · doi:10.1097/md.0000000000020875 · Cited by 17
Neumiller, J. J., Alicic, R. Z., & Tuttle, K. R. (2023) · Clinical Kidney Journal · doi:10.1093/ckj/sfad285 · Cited by 18
Efficacy and Safety of Sotagliflozin in Patients with Type 1 Diabetes and CKD
Sridhar, V. S., Odutayo, A., Garg, S. V., Danne, T., Doria, A., Mauer, M. S., Davies, M. J., Banks, P. L., Girard, M., & Cherney, D. Z. I. (2024) · Journal of the American Society of Nephrology · doi:10.1681/asn.0000000540 · Cited by 19
“10 – 12 The inTandem 1 and 2 studies were both 52-week (with ef fi cacy and safety end points collected at baseline and weeks 4, 8, 12, 16, 20, 24 [primary ef fi cacy time point], 32, 40, and 52), placebo-controlled, randomized trials evaluating the ef fi cacy and safety of sotagli fl ozin 200 and 400…”
Self-citationEmpagliflozin in type 1 diabetes
Mathieu, C., den Mooter, L. V., & Eeckhout, B. (2019) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s194688 · Cited by 19
“Of interest, sotagliflozin increased the time in range with more than 3 h, without increasing the time in hypoglycemia.(18,19)”
BackgroundA perspective on treating type 1 diabetes mellitus before insulin is needed
Tatović, D., Narendran, P., & Dayan, C. M. (2023) · Nature Reviews Endocrinology · doi:10.1038/s41574-023-00816-5 · Cited by 34
Nan, J., Wang, D., Zhong, R., Liu, F., Luo, J., Tang, P., Song, X., & Zhang, L. (2023) · Primary care diabetes · doi:10.1016/j.pcd.2023.10.010 · Cited by 16
Overweight and Obesity in Adults with Type 1 Diabetes: A Growing Challenge
Majanović, S. K., Detel, D., Igrec, M., Bergoč, A., Rahelić, V., & Rahelić, D. (2024) · Diabetology · doi:10.3390/diabetology5030018 · Cited by 22
“However, it seems reasonable to assume that subjects with T1D and obesity, who are unable to accomplish a significant and sustained weight loss with lifestyle interventions, may benefit from pharmacotherapy in real life [78].”
BackgroundGlycaemic variabilities: Key questions in pursuit of clarity
Monnier, L., Owens, D. R., Colette, C., & Bonnet, F. (2021) · Diabetes & Metabolism · doi:10.1016/j.diabet.2021.101283 · Cited by 16
Herring, R. A., Shojaee‐Moradie, F., Garesse, R., Stevenage, M., Jackson, N., Fielding, B. A., Mendis, A., Johnsen, S., Umpleby, A. M., Davies, M. J., et al. (2020) · Diabetes Care · doi:10.2337/dc19-2579 · Cited by 16
“4% in the placebo group over 24 weeks (6).”
BackgroundLangford, B., Evans, M., Haskins‐Coulter, T., O'Connor, M., Cant, H. E. O., Eddowes, L. A., Edmonds, C., & Tank, A. (2019) · Diabetes Obesity and Metabolism · doi:10.1111/dom.13863 · Cited by 15
“2%) experiencing ≥1 DKA AE at Week 24 and Week 52, respectively.(33,41) The rare nature of DKA AEs in the clinical studies reduced the statistical power for the NMAs, leading to wide credible intervals and limiting the usefulness of the results because of their uncertainty.”
BackgroundStrategically Playing with Fire: SGLT Inhibitors as Possible Adjunct to Closed-Loop Insulin Therapy
Pasqua, M., Tsoukas, M. A., & Haidar, A. (2021) · Journal of Diabetes Science and Technology · doi:10.1177/19322968211035411 · Cited by 18
STOUGAARD, E. B., Rossing, P. R., Cherney, D. Z. I., Vistisen, D., & Persson, F. (2022) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2022.108257 · Cited by 15
Geng, L., Sun, B., & Chen, Y. (2024) · Diabetes Obesity and Metabolism · doi:10.1111/dom.15901 · Cited by 17
Li, M., Liu, Z., Yang, X., Zhang, J., Han, M., Zhang, Y., & Liu, Y. (2023) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2023.108632 · Cited by 14
Metadata
- Authors
- Buse, J. B., Garg, S. K., Rosenstock, J., Bailey, T. S., Banks, P., Bode, B. W., Danne, T., Kushner, J. A., Lane, W. S., Lapuerta, P., McGuire, D. K., Peters, A. L., Reed, J., Sawhney, S., & Strumph, P.
- Affiliations
- University of North Carolina at Chapel Hill (US)
- University of Colorado Anschutz (US)
- Dallas Diabetes Research Center (US)
- AMCR Institute (US)
- Lexicon Pharmaceuticals (United States) (US)
- Emory University (US)
- Medizinische Hochschule Hannover (DE)
- Baylor College of Medicine (US)
- Mountain Diabetes and Endocrine Center (US)
- The University of Texas Southwestern Medical Center (US)
- University of Southern California (US)
- Endocrine Research Solutions (United States) (US)
- Corresponding author
- Buse, John B.
- ORCID
- Venue
- Diabetes Care
- Publisher
- American Diabetes Association
- Published
- 2018-06-24
- Volume
- 41
- Issue
- 9
- Pages
- 1970-1980
- ISSN
- 0149-5992 (ISSN-L)
- 1935-5548
- PMC
- PMC6105319
- OpenAlex
- W2809153459
- Cited by
- 234
- References
- 41
- Citations by year
- 2026: 19 · 2025: 27 · 2024: 24 · 2023: 26 · 2022: 16 · 2021: 22 · 2020: 39 · 2019: 49 · 2018: 12
- FWCI
- 24.47
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Diabetes Care (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institutes of Health (UL1TR001111, UL1TR002489)
- National Center for Advancing Translational Sciences
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Diabetes and associated disorders
- Keywords
- sotagliflozin, type 1 diabetes, glycemic control, HbA1c, weight loss, insulin dose reduction, diabetes treatment satisfaction, genital mycotic infections, diarrhea, diabetic ketoacidosis, adults with type 1 diabetes, drug safety and efficacy
- MeSH terms
- Adult, Aged, Body Weight, Diabetes Mellitus, Type 1, Double-Blind Method, Drug Therapy, Combination, Female, Glycosides, Glycated Hemoglobin, Humans, Hypoglycemia, Insulin, Insulin Infusion Systems, Male, Middle Aged, North America, Weight Loss, Diabetic Ketoacidosis
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.